๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo

โœ Scribed by J.Y. Henry; L. Lu; M. Adams; B. Meyer; J.B. Bartlett; Prof. A.G. Dalgleish; C. Galustian

Book ID
112179565
Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
554 KB
Volume
72
Category
Article
ISSN
0270-4137

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

BMI1 silencing enhances docetaxel activi
BMI1 silencing enhances docetaxel activity and impairs antioxidant response in prostate cancer
โœ Francesco Crea; Maria A. Duhagon Serrat; Elaine M. Hurt; Suneetha B. Thomas; Rom ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 326 KB

## Abstract The BMI1 oncogene promotes prostate cancer (PC) progression. High Bโ€cellโ€specific Moloney murine leukemia virus integration site 1 (BMI1) expression predicts poor prognosis in PC patients. Recent evidence suggests that BMI1 may also play a role in docetaxel chemoresistance. However, mec

Pretreatment of docetaxel enhances TRAIL
Pretreatment of docetaxel enhances TRAIL-mediated apoptosis in prostate cancer cells
โœ Jinsang Yoo; Sung-Soo Park; Yong J. Lee ๐Ÿ“‚ Article ๐Ÿ“… 2008 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 367 KB ๐Ÿ‘ 1 views

## Abstract Tumor necrosis factorโ€related apoptosisโ€inducing ligand (TRAIL) is a promising cancer therapeutic agent because of its tumor selectivity. TRAIL is known to induce apoptosis in cancer cells but spare most normal cells. In this study, we examined whether treatment of docetaxel (DTX) can e